David F Katz1, Mintu P Turakhia2, William H Sauer2, Wendy S Tzou2, Russell R Heath2, Matthew M Zipse2, Ryan G Aleong2, Paul D Varosy2, David P Kao2. 1. From the University of Colorado, Aurora (D.F.K., W.H.S., W.S.T., M.M.Z., R.G.A., P.D.V., D.P.K.); VA Palo Alto Health Care System, Stanford University, CA (M.P.T.); University of Colorado Health, Fort Collins (R.R.H.); and Eastern Colorado VA Medical Center, Denver (P.D.V.). David.Katz@UCDenver.edu. 2. From the University of Colorado, Aurora (D.F.K., W.H.S., W.S.T., M.M.Z., R.G.A., P.D.V., D.P.K.); VA Palo Alto Health Care System, Stanford University, CA (M.P.T.); University of Colorado Health, Fort Collins (R.R.H.); and Eastern Colorado VA Medical Center, Denver (P.D.V.).
Abstract
BACKGROUND: Outcomes of ventricular tachycardia (VT) ablation have been described in clinical trials and single-center studies. We assessed the safety of VT ablation in clinical practice. METHODS AND RESULTS: Using administrative hospitalization data between 1994 and 2011, we identified hospitalizations with primary diagnosis of VT (International Classification of Diseases-9 Clinical Modification code: 427.1) and cardiac ablation (International Classification of Diseases-9 Clinical Modification code: 37.34). We quantified in-hospital adverse events (AEs), including death, stroke, intracerebral hemorrhage, pericardial complications, hematoma or hemorrhage, blood transfusion, or cardiogenic shock. Secondary outcomes included major AEs (stroke, tamponade, or death) and death. Multivariable mixed effects models identified patient and hospital characteristics associated with AEs. Of 9699 hospitalizations with VT ablations (age, 56.5 ± 17.6; 60.1% men), AEs were reported in 825 (8.5%), major AEs in 295 (3.0%), and death in 110 (1.1%). Heart failure had the strongest association with death (odds ratio, 5.52; 95% confidence interval, 2.97-10.3) and major AE (odds ratio, 2.99; 95% confidence interval, 2.15-4.16). Anemia (odds ratio, 4.84; 95% confidence interval, 3.79-6.19) and unscheduled admission (odds ratio, 1.64; 95% confidence interval, 1.37-1.97) were associated with AEs. During the study period, incidence of AEs increased from 9.2% to 12.8% as did the burden of AE risk factors (0.034 patient/y; P < 0.001). Hospital volume > 25 cases/y was associated with fewer AEs compared with lower volume centers (6.4% versus 8.8%; P = 0.008). CONCLUSIONS: VT ablation-associated AE rates in clinical practice are similar to those reported in the literature. Over time rates have increased as have the number of AE risk factors per patient. Ablations done electively and at hospitals with higher procedural volume are associated with lower incidence of AEs.
BACKGROUND: Outcomes of ventricular tachycardia (VT) ablation have been described in clinical trials and single-center studies. We assessed the safety of VT ablation in clinical practice. METHODS AND RESULTS: Using administrative hospitalization data between 1994 and 2011, we identified hospitalizations with primary diagnosis of VT (International Classification of Diseases-9 Clinical Modification code: 427.1) and cardiac ablation (International Classification of Diseases-9 Clinical Modification code: 37.34). We quantified in-hospital adverse events (AEs), including death, stroke, intracerebral hemorrhage, pericardial complications, hematoma or hemorrhage, blood transfusion, or cardiogenic shock. Secondary outcomes included major AEs (stroke, tamponade, or death) and death. Multivariable mixed effects models identified patient and hospital characteristics associated with AEs. Of 9699 hospitalizations with VT ablations (age, 56.5 ± 17.6; 60.1% men), AEs were reported in 825 (8.5%), major AEs in 295 (3.0%), and death in 110 (1.1%). Heart failure had the strongest association with death (odds ratio, 5.52; 95% confidence interval, 2.97-10.3) and major AE (odds ratio, 2.99; 95% confidence interval, 2.15-4.16). Anemia (odds ratio, 4.84; 95% confidence interval, 3.79-6.19) and unscheduled admission (odds ratio, 1.64; 95% confidence interval, 1.37-1.97) were associated with AEs. During the study period, incidence of AEs increased from 9.2% to 12.8% as did the burden of AE risk factors (0.034 patient/y; P < 0.001). Hospital volume > 25 cases/y was associated with fewer AEs compared with lower volume centers (6.4% versus 8.8%; P = 0.008). CONCLUSIONS: VT ablation-associated AE rates in clinical practice are similar to those reported in the literature. Over time rates have increased as have the number of AE risk factors per patient. Ablations done electively and at hospitals with higher procedural volume are associated with lower incidence of AEs.
Authors: Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Saenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld Journal: J Interv Card Electrophysiol Date: 2020-10 Impact factor: 1.900
Authors: Edmond M Cronin; Frank M Bogun; Philippe Maury; Petr Peichl; Minglong Chen; Narayanan Namboodiri; Luis Aguinaga; Luiz Roberto Leite; Sana M Al-Khatib; Elad Anter; Antonio Berruezo; David J Callans; Mina K Chung; Phillip Cuculich; Andre d'Avila; Barbara J Deal; Paolo Della Bella; Thomas Deneke; Timm-Michael Dickfeld; Claudio Hadid; Haris M Haqqani; G Neal Kay; Rakesh Latchamsetty; Francis Marchlinski; John M Miller; Akihiko Nogami; Akash R Patel; Rajeev Kumar Pathak; Luis C Sáenz Morales; Pasquale Santangeli; John L Sapp; Andrea Sarkozy; Kyoko Soejima; William G Stevenson; Usha B Tedrow; Wendy S Tzou; Niraj Varma; Katja Zeppenfeld Journal: Europace Date: 2019-08-01 Impact factor: 5.214
Authors: Alan Sugrue; Christopher V DeSimone; Charles J Lenz; Douglas L Packer; Samuel J Asirvatham Journal: J Interv Card Electrophysiol Date: 2015-12-09 Impact factor: 1.900
Authors: Gbolahan O Ogunbayo; Katrina Bidwell; Naoki Misumida; Le Dung Ha; Ahmed Abdel-Latif; Claude S Elayi; Susan Smyth; Adrian W Messerli Journal: Clin Cardiol Date: 2018-04-19 Impact factor: 2.882
Authors: Veronica Dusi; Jeffrey Gornbein; Duc H Do; Julie M Sorg; Houman Khakpour; Yuliya Krokhaleva; Olujimi A Ajijola; Carlos Macias; Jason S Bradfield; Eric Buch; Osamu A Fujimura; Noel G Boyle; Jane Yanagawa; Jay M Lee; Kalyanam Shivkumar; Marmar Vaseghi Journal: J Am Heart Assoc Date: 2021-01-14 Impact factor: 5.501
Authors: José-Luis López-Sendón; José Ramón González-Juanatey; Fausto Pinto; José Cuenca Castillo; Lina Badimón; Regina Dalmau; Esteban González Torrecilla; José Ramón López Mínguez; Alicia M Maceira; Domingo Pascual-Figal; José Luis Pomar Moya-Prats; Alessandro Sionis; José Luis Zamorano Journal: Eur Heart J Date: 2015-10-21 Impact factor: 29.983